Need to keep on prime of the science and politics driving biotech at this time? Join to get our biotech e-newsletter in your inbox.
Good morning, everybody. Damian right here with the plight of the enterprise capitalist, an thought for Gilead Sciences, and the newest within the quest to search out potent therapies for Parkinson’s illness.
The necessity-to-know this morning
- Most cancers drug developer CG Oncology raised $380 million in an preliminary public providing. It’s the primary biotech IPO of 2024.
Biotech VCs are feeling the squeeze
As fledgling drug corporations battle to lift the money they should survive, spare a second for the enterprise capitalists on the opposite aspect of the Zoom display.